Instapath

Executive Summary

Instapath is a Houston-based diagnostics company that has developed a novel platform enabling rapid, point-of-procedure pathology assessment. Its technology transforms fresh tissue samples into high-resolution digital images in minutes without the need for cutting, fixing, or embedding, preserving the sample for downstream analytical testing. This innovation addresses a critical bottleneck in surgical pathology, where traditional frozen section analysis is time-consuming and can compromise tissue integrity. By providing instant, high-quality digital pathology at the point of care, Instapath aims to accelerate diagnostic workflows, reduce intraoperative wait times, and improve patient outcomes in surgical and biopsy settings. The platform's ability to deliver real-time pathology insights without tissue loss positions it as a transformative tool in oncology and minimally invasive procedures. With the global digital pathology market expected to grow significantly, Instapath is well-placed to capture value by partnering with hospitals and surgical centers. However, as a private company still in early commercialization, key execution risks include regulatory clearance, clinical validation, and adoption by pathologists. If successful, Instapath could become a standard adjunct to conventional pathology, offering speed and efficiency gains that align with the shift toward value-based care.

Upcoming Catalysts (preview)

• Q4 2026FDA 510(k) clearance or Breakthrough Device designation40% success
• Q3 2026Pilot partnership with a major hospital system for intraoperative use55% success
• H2 2026Series B funding round to support commercialization60% success